Bicara Therapeutics Statistics
Total Valuation
BCAX has a market cap or net worth of $997.03 million. The enterprise value is $708.84 million.
Important Dates
The last earnings date was Monday, November 10, 2025, before market open.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BCAX has 54.78 million shares outstanding. The number of shares has increased by 1,559.37% in one year.
| Current Share Class | 54.78M |
| Shares Outstanding | 54.78M |
| Shares Change (YoY) | +1,559.37% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 2.19% |
| Owned by Institutions (%) | 48.98% |
| Float | 24.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.47 |
| P/TBV Ratio | 2.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.14 |
| Quick Ratio | 13.80 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.64% and return on invested capital (ROIC) is -19.28%.
| Return on Equity (ROE) | -26.64% |
| Return on Assets (ROA) | -18.59% |
| Return on Invested Capital (ROIC) | -19.28% |
| Return on Capital Employed (ROCE) | -34.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.21M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCAX has paid $350,000 in taxes.
| Income Tax | 350,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.77% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.77% |
| 50-Day Moving Average | 16.63 |
| 200-Day Moving Average | 13.04 |
| Relative Strength Index (RSI) | 57.80 |
| Average Volume (20 Days) | 655,022 |
Short Selling Information
The latest short interest is 7.22 million, so 13.18% of the outstanding shares have been sold short.
| Short Interest | 7.22M |
| Short Previous Month | 6.46M |
| Short % of Shares Out | 13.18% |
| Short % of Float | 29.73% |
| Short Ratio (days to cover) | 9.47 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -141.12M |
| Pretax Income | -121.17M |
| Net Income | -121.52M |
| EBITDA | -141.04M |
| EBIT | -141.12M |
| Earnings Per Share (EPS) | -$2.23 |
Full Income StatementBalance Sheet
The company has $290.17 million in cash and $1.98 million in debt, giving a net cash position of $288.19 million or $5.26 per share.
| Cash & Cash Equivalents | 290.17M |
| Total Debt | 1.98M |
| Net Cash | 288.19M |
| Net Cash Per Share | $5.26 |
| Equity (Book Value) | 402.78M |
| Book Value Per Share | 7.38 |
| Working Capital | 276.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$112.98 million and capital expenditures -$82,000, giving a free cash flow of -$113.06 million.
| Operating Cash Flow | -112.98M |
| Capital Expenditures | -82,000 |
| Free Cash Flow | -113.06M |
| FCF Per Share | -$2.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |